By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Alzheimer’s Drug Development: An Avant-Garde Approach
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Alzheimer’s Drug Development: An Avant-Garde Approach
Medical InnovationsSpecialties

Alzheimer’s Drug Development: An Avant-Garde Approach

Deanna Pogorelc
Deanna Pogorelc
Share
3 Min Read
SHARE

alzheimer's disease

Originally published on MedCityNews.com.

alzheimer's disease

Originally published on MedCityNews.com.

More Read

5 Things To Do For A Parent With Dementia Or Early Stage Alzheimer’s
The Most Important Things To Know When Choosing A Chiropractor
Study Finds Nursing Homes Have Inadequate Care and Discharge Planning
Urinalysis Via Mobile App
5 Benefits of Orthopedic Group Purchasing

A handful of high-profile Alzheimer’s disease drugs have failed in late-stage clinical trials in the last year — at least two of them based on the hypothesis that buildup of amyloid plaques in the brain give rise to neurodegeneration. Startup T3D Therapeutics Inc. thinks that warrants a different approach to a disease-altering therapeutic.

“Alzheimer’s disease involves multiple abnormalities, yet the pharmaceutical industry has placed heavy bets on developing treatments for just one abnormality,” said founder and CEO John Didsbury.

T3D claims it’s developing a drug with the potential to address several disease pathologies, including beta-amyloid plaque issues, inflammation, neuronal cell loss, neurotransmitter deficits, insulin deficiency and tau neurofibrillary tangles. And it would come in the form of a once-a-day pill for people with mild to moderate Alzheimer’s.

The Durham, North Carolina company licensed its technology from specialty pharmaceutical company DARA BioSciences, where Didsbury formerly served as president and chief operating officer. DARA had developed the drug candidate, now called T3D-959, through Phase I clinical trials as a treatment for diabetes and dyslipidemia. Thus, Didsbury said a key piece of T3D’s approach to altering the course of Alzheimer’s is insulin regulation.

Researchers have been studying a link between insulin dysregulation and Alzheimer’s for almost a decade. T3D sees insulin deficiency as a trigger for the abnormalities that lead to neurodegeneration.

“Clinical symptoms never occur without sugar metabolism decreases in the brain, which results from neurons becoming resistant to insulin,” he said. “Without the ability to use insulin to access sugar as an energy source, neurons die. T3D-959 acts as a powerful insulin sensitizer.”

Didsbury said the company just closed an oversubscribed seed round this summer, which SEC filings indicate targeted $550,000, and just opened a Series A round. “We will be using those funds to do pre-clinical trials and a pilot clinical trial in Alzheimer’s disease,” he said.

For his part, Didsbury has assembled a supporting cast of science and pharmaceutical business veterans and an advisory board that includes a key developer of Alzheimer’s drug Aricept and the chief of neurology at Duke University Medical Center. The CEO has served in the C-suites of several pharma companies over the last two decades, including NovaTarg and GlaxoSmithKline.

“It has been a personal mission of mine for the last 25 years in the pharmaceutical industry to identify and develop a breakthrough medicine,” Didsbury said. “This is the culmination of that search.”

[Image credit: Flickr user GreenFlames09]

TAGGED:Alzheimer's Diseasehealth start-ups!
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

Screen Shot 2015-08-28 at 1.53.57 PM
Medical InnovationsTechnology

Medtech: Numbers and Size of Fundings, Jan-Aug 2015

August 31, 2015

The PCMH and Home Care Data: An Interview with Melissa McCormack

December 19, 2013

Drawing an Infographic Line on Healthcare’s Future

September 5, 2012
ebola gene sequencing
eHealthGlobal HealthcareMedical InnovationsNewsTechnology

Next-Gen Sequencing Could Unlock Ebola’s Secrets

September 29, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?